Scientific presentations

Oncopeptides presented positive topline results from the phase 3 OCEAN and hosted a webcast Tuesday May 25, 2021.

Oncopeptides hosted a webcast on Wednesday, December 9th at 14:00 (CET) to provide an update regarding data presented at the ASH annual meeting. The webcast was recorded and hosted by CEO Marty J Duvall, CSO Jakob Lindberg and CMO Klaas Bakker.

Oncopeptides presented new data from phase 2 ANCHOR combination study in multiple myeloma the 62nd American Society of Hematology virtual annual meeting ASH, December 6, 2020.

Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients. On June 16 at 10:00 (CET), CEO Jakob Lindberg comments on the top-line results.

Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients as well as several other posters during EHA.

Oncopeptides hosted a webcast to present the HORIZON study data and provided a general clinical update March 26, 2020.

Oncopeptides hosted a webcast on Monday, January 27th 2020 were CEO Jakob Lindberg presented and explained melflufen’s mechanism of action. Investors, analysts and the media were invited to the webcast.

Oncopeptides CEO Jakob Lindberg summarized our data and presentations post ASH in a webcast December 10, 2019.

Poster presentations held at ASH 2019.

Oncopeptides to highlight data from melflufen clinical program in multiple myeloma and AL Amyloidosis in six presentations at ASH Annual Meeting 2019.

In New York, USA, Oncopeptides presented three posters at the Lymphoma & Myeloma Congress 2019. See the posters below.

Oncopeptides presented one poster at the ESMO meeting in Barcelona, Spain. See the Poster below.

Oncopeptides presented new interim data in RRMM Patients with Extramedullary Disease (EMD) from the Pivotal Phase 2 Horizon-study at the 17th International Myeloma Workshop (IMW) meeting in Boston, Massachusetts, USA. The data focused on patients with extramedullary disease (EMD) and was presented in an oral presentation by Professor Paul G. Richardson.

Oncopeptides presented two poster at the 17th International Myeloma Workshop (IMW) meeting in Boston, Massachusetts, USA. See the Posters below.

At the Society of Hematologic Oncology (SOHO) 2019 Annual Meeting in Houston, TX, USA, clinical trial data from two of our trials HORIZON and ANCHOR were presented. In an oral presentation, data from the pivotal Phase 2 HORIZON clinical trial were presented as part of the meeting’s multiple myeloma session. Additionally, two posters focused on the ANCHOR and HORIZON clinical trials evaluating melflufen in RRMM were displayed at the meeting.

During 2019 European Hematology Association (EHA) Congress, Oncopeptides presented updated interim data from the ongoing phase 1/2 ANCHOR study, data from its phase 1/2 O-12-M1 study and updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial. These presentations as well as publications in the media are presented below. The ANCHOR and O-12-M1 Posters, the oral presentation of HORIZON by Professor Paul G. Richardson and several external links and videos regarding publications in the media.

During 2019 ASCO General Meeting (American Society of Clinical Oncology), Oncopeptides presented new data from phase 1/2 O-12-M1 trial evaluating melflufen in RRMM. These data was presented by Professor Paul G. Richardson.

Oncopeptides hosted a webcast on Monday, 17 June to review and update presentations from European Hematology Association (EHA) meeting. It was presented by CEO Jakob Lindberg and members of the Oncopeptides management team.

Professor Paul G. Richardson held an oral presentation of the study HORIZON at EHA 2019 on 16 June.

Poster presentations at EHA June 14th, 2019.

New data from Oncopeptides phase 1/2 O-12-M1 trial evaluating melflufen in RRMM presented at 2019 ASCO annual meeting by Professor Paul G. Richardson.

Upcoming presentations at EHA - four abstracts from Oncopeptides

Oncopeptides has a poster presentation of data from its Phase 1/2 O-12-M1 study at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4 in Chicago. The study evaluates melflufen in the treatment of relapsed/refractory multiple myeloma (RRMM), Melflufen is a lipophilic peptide-conjugated alkylator belonging to the novel class of Peptidase Enhanced Cytotoxics (PEnC).

At the AACR (American Association for Cancer Research) Annual Meeting 2019 Oncopeptides presented two Posters for the studies ANCHOR and HORIZON.

During the American Hematology Meeting (ASH), Oncopeptides presented data from two ongoing studies, ANCHOR and HORIZON.

Horizon Poster (9 Dec 2017) and O-12-M1 Poster (10 Dec 2017).

Professor Paul G. Richardson presentation at ASH 2018 – The HORIZON study.

ANCHOR poster. Oncopeptides presents the first interim data with melflufen (Ygalo®) from the ongoing phase I/II study ANCHOR at the 60th ASH meeting in San Diego, California, USA (December 1, 2018).

Oncopeptides to present updated data from the two ongoing trials ANCHOR and HORIZON in patients with RRMM at ASH in December 2018. The abstract data cut for ANCHOR was July 18th and for HORIZON, May 10th. Further data supporting melflufen’s activity has been generated since the abstract data cut and will be presented at ASH.

The updated phase II-data show a clinical data set with an Overall Response Rate (ORR) of 32.1% and a Clinical Benefit Rate (CBR) of 39.3% with Ygalo® in relapsed/refractory multiple myeloma patients refractory to pomalidomide and/or daratumumab after failing on immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs).

Oncopeptides had a press conference on December 13, 2018. View the recorded webcast.